HighTower Advisors
OCUL icon

HighTower Advisors’s Ocular Therapeutix OCUL Stock Holding History

HighTower Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,768
Closed -$121K – 3899
2024
Q2 		$121K Hold
17,768
– – ﹤0.01% 3165
2024
Q1 		$163K Buy
17,768
+1,630
+10% +$11.6K ﹤0.01% 3039
2023
Q4 		$72K Sell
16,138
-4,000
-20% -$11.8K ﹤0.01% 3257
2023
Q3 		$63K Sell
20,138
-600
-3% -$2.46K ﹤0.01% 3194
2023
Q2 		$107K Sell
20,738
-330
-2% -$1.96K ﹤0.01% 3058
2023
Q1 		$112K Hold
21,068
– – ﹤0.01% 2913
2022
Q4 		$59K Sell
21,068
-700
-3% -$2.32K ﹤0.01% 3005
2022
Q3 		$90K Hold
21,768
– – ﹤0.01% 2785
2022
Q2 		$87K Hold
21,768
– – ﹤0.01% 2818
2022
Q1 		$108K Buy
21,768
+2,500
+13% +$13.9K ﹤0.01% 2973
2021
Q4 		$134K Buy
19,268
+6,500
+51% +$50.5K ﹤0.01% 2873
2021
Q3 		$128K Buy
12,768
+2,500
+24% +$28.1K ﹤0.01% 2818
2021
Q2 		$146K Sell
10,268
-1,016
-9% -$15.4K ﹤0.01% 2730
2021
Q1 		$185K Sell
11,284
-1,376
-11% -$26.5K ﹤0.01% 2633
2020
Q4 		$261K Buy
+12,660
New +$188K ﹤0.01% 2028
2020
Q3 		– Sell
-95,639
Closed -$790K – 2645
2020
Q2 		$790K Buy
+95,639
New +$634K ﹤0.01% 1221

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors's OCUL Position: Q3 2024 in Review

HighTower Advisors sold out of Ocular Therapeutix (OCUL) in Q3 2024, closing a stake of 17,768 shares — an estimated $121K sold.

HighTower Advisors first reported a position in OCUL in Q2 2020 and held it in 16 quarters. The position peaked at $790K in Q2 2020. 168 funds tracked by Wall St. Rank hold OCUL as of Q3 2024.

  • HighTower Advisors reported no remaining Ocular Therapeutix position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 17,768 Ocular Therapeutix shares in Q3 2024, an estimated $121K.
  • HighTower Advisors first reported a position in Ocular Therapeutix in Q2 2020 and held it in 16 quarters.
  • HighTower Advisors's Ocular Therapeutix position peaked at $790K in Q2 2020.
  • 168 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.